Cancer is the fourth leading cause of death in adolescent and young adults (AYA: ages15-39) worldwide. Over 90% of AYAs with cancer live in low-and-middle-incomecountries (LMIC). Little is known about thecurrent landscape of AYA oncology care in these settings. Guidelines for the care of thisunique population in LMIC in Latin America are lacking.
It often presents during and after treatment with memory impairment, concentration deficits, and depression. 25.75% prevalence in adolescent and young adult (AYA) cancer survivors. It significantly impacts school, work, daily activities, and overall quality of life.
Retroperitoneal sarcomas (RPS) are rare tumors accounting for 1%–2% of all solid malignancies and 10%–20% of sarcomas. Surgery is the main treatment modality for patients with RPS. To date, there is no established model to predict perioperative risks for RPS patients. In this study, we evaluate the association between preoperative sarcopenia,hypoalbuminemia, and frailty and 30-dayperioperative morbidity and survival in patientswith RPS undergoing surgical resection. Ourgoal is to determine the ability of these factorsto predict surgical and oncological outcomes inthese cases.
Endometriosis: ectopic endometrial tissue that responds to cyclical hormonal changes during a normal menstrual cycle, becoming trapped in an endometrioma and causing pain. NHPs have been used to study endometriosis: baboons, cynomolgus, rhesus, and marmoset monkeys.
Compound 10357 is an amiloride derivative with potential promise as an adjunct to current chemotherapeutics. This study investigates the therapeutic efficacy of Compound 10357 in B-Cell Acute Lymphoblastic Leukemia (B-ALL).
Lung cancer is the leading cause of both cancer and cancer-related mortality in the United States. Targeting different receptor tyrosine kinase pathways has proven to be a potent therapeutic strategy for such cancers.
Lung cancer is the leading cause of cancer related deaths in the US, with 85% of cases classified as non-small cell lung cancer (NSCLC). 20-25% of patients with NSCLC present with resectable disease.
